T-MAXIMUM’s off-the-shelf CAR-T shrank brain tumors in early testing. Can Phase 2 confirm the signal?
T-MAXIMUM has received FDA clearance to initiate a Phase 2 study of MT027 in brain metastases from lung and breast cancer. Early results in a small lung cancer cohort support further investigation, but clinical efficacy, neurological safety and manufacturing scalability remain unproven.